PACTR2010060002033537
Completed
未知
A phase II, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in Gabonese, Bukinabe, Ghanaian, and Ugandan children aged 12 to 60 months
Statens Serum Intitute0 sites1,840 target enrollmentApril 7, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malaria
- Sponsor
- Statens Serum Intitute
- Enrollment
- 1840
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Children aged 12 \- 60 months inclusive at the time of the first dose
- •2\.Healthy by medical history and physical examination
- •3\.Signed or thumb\-printed Informed Consent by guardian/parent. Where guardian/parent cannot sign, a witness will be asked to sign to indicate that the procedures were understood and consent was given.
- •4\.Resident in the study villages during the whole clinical trial period
Exclusion Criteria
- •1\.Symptoms, physical signs of disease that could interfere with the interpretation of the clinical trial results or compromise the health of the subjects if they were vaccinated
- •2\.Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within three (3\) months prior recruitment. (for corticosteroids, this will mean prednisone, or equivalent, ¿ 0\.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •3\.Cannot be followed for any social, psychological or geographical reasons.
- •4\.Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to the end of the child¿s participation in this clinical trial.
- •5\.Suspected or known hypersensitivity to any of the vaccine components or to any vaccine.
- •6\.Acute or chronic, clinically significant hepatic or renal functional abnormality.
- •7\.Anaemia associated with clinical signs or symptoms of decompensation or haemoglobin \< 7\.0 g/dL.
- •8\.Planned administration of a vaccine not foreseen by the trial protocol within 30 days of the first dose of vaccine. An exception, is the receipt of an EPI or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria/ pertussis/ tetanus vaccines) which may be given 14 days or more before or after vaccination
- •9\.Presence of chronic illness that, in the judgement of the investigator, would interfere with the study outcomes or pose a threat to the participant¿s health.
- •10\.Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A clinical study to evaluate the efficacy to stop the bleeding and safety of TT-173 applied in the donor site of patients undergoing skin graft.EUCTR2013-002784-25-ESThrombotargets Europe
Active, not recruiting
Not Applicable
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyRheumatoid arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2009-012041-35-BEeovacs SA48
Active, not recruiting
Not Applicable
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyRheumatoid arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2009-012041-35-BGeovacs SA48
Completed
Phase 2
A phase II study of the Cuban adult formulation tetanus and diphtheria vaccine.tetanus and diphtheriaTetanusDiphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsRPCEC00000059Finlay Institute225
Completed
Phase 2
A phase II study of the Cuban vaccine against tetanus and diphtheria VA-DIFTET.tetanus and diphtheriaTetanusDiphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsRPCEC00000058Finlay Institute300